Researchers from the Mayo Clinic in Rochester, Minn. examined the disease histology and outcomes of patients with diffuse large B-cell lymphoma and a concurrent lymphoma.
In this phase II GALEN study, researchers examined the effects of lenalidomide and obinutuzumab in patients with relapsed or refractory follicular lymphoma.
A new study looked at the rates of response and remission in patients with relapsed or refractory follicular lymphoma who underwent CD19-directed CAR-T cell therapy.
The CALGB 50904 trial tested the addition of bortezomib to ofatumumab and bendamustine in patients with previously untreated high-risk follicular lymphoma.
A Mayo Clinic study tested metformin, believed to have anti-lymphoma activity, among patients with newly diagnosed diffuse large B-cell lymphoma or follicular lymphoma.
Patients with follicular lymphoma or diffuse large B-cell lymphoma with a low peripheral blood natural killer cell count at baseline had shorter time to progression.
Researchers have found several characteristics identified on PET/CT that may help to predict early clinical failure of untreated follicular lymphoma.
Researchers compared the newly developed PRIMA-PI risk score against FLIPI and FLIPI-2 in patients with follicular lymphoma.
A retrospective study supported the role of primary radiotherapy in early-stage follicular lymphoma.
The FDA has granted Priority Review to Celgene’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma.